Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
RNA Pol II Inhibitor-Bacteria by Hamlet Pharma for Inflammation: Likelihood of Approval
RNA Pol II Inhibitor-Bacteria is under clinical development by Hamlet Pharma and currently in Phase I for Inflammation. According to...